Cancer Biology

项目总结（见说明）：癌症生物学项目（CB）的科学目标是了解定义正常和肿瘤细胞生长的分子机制，以识别和表征参与肿瘤发生、生长和进展的分子、途径和过程。CB是一个新的计划，代表KUCC的基础科学倡议，并通过成员利用分子，生物化学和基于细胞的方法来研究癌细胞的异常行为。CB的总体目标是促进合作，促进可以从实验室到床边转化的基本发现。CB的具体目标是：1）促进合作，加强对肿瘤发生、进展和恶性行为背后的细胞、分子和生化机制的发现; 2）利用基础科学发现，激发新型癌症疗法的临床前和临床开发。CB有32个正式成员和11个准成员，代表KUCC的所有机构。即使在KUCC发展的早期阶段，CB也获得了1700万美元的癌症相关同行评审资金，其中190万美元来自NCI，1510万美元来自其他同行评审赞助商。从2006年到2010年，成员发表了250篇癌症相关的同行评审论文，被引用2904次（平均10.8次引用/发表），其中7%是项目间互动的结果，15%来自项目内互动。此外，2010年，CB计划成员占生物样本共享资源使用量的10.2%，占生物统计学和信息学共享资源使用量的7.09%，占铅开发和优化共享资源使用量的8.57%。CB由Yvonne Wan和Linheng Li共同领导，他们带来了互补的科学专业知识，不断增长的领导经验和多样化的机构代表。他们将与丹尼·R密切合作。韦尔奇，基础科学副主任。CB利用了KUMC、KU-Lawrence和Stowers研究所在肝脏、GI、肾脏和造血肿瘤方面的历史优势。最近的招聘已经扩大了这些举措，包括乳腺癌，HNSCC和骨肉瘤研究。除了基于疾病的主题组织，CB成员的专业知识可以分为四个学科为基础的主题-染色质组织和转录调控，信号通路和发展，癌细胞生物学和干细胞生物学;和细胞增殖，分化和死亡，

PROJECT SUMMARY (See instructions): The scientific goal of the Cancer Biology program (CB) is to understand the molecular mechanisms that define normal and neoplastic cell growth in order to identify and characterize molecules, pathways and processes that are involved in tumor development, growth and progression. CB is a new program that represents the basic science initiatives of KUCC and is unified by member utilization of molecular, biochemical, and cell-based approaches that study the aberrant behavior of cancer cells. The overarching goal of CB is to catalyze collaborations that promote basic discoveries that can be translated from bench-to-bedside. The Specific Aims of CB are 1) to promote collaboration that enhances discovery of the cellular, molecular and biochemical mechanisms that underlie tumor development, progression and malignant behavior; and 2) to leverage basic science discoveries to inspire pre-clinical and clinical development of novel cancer therapies. CB has 32 full members and 11 associate members, representing all KUCC institutions. Even at this early stage of KUCC growth, CB has garnered $17 million in cancer-related, peer-reviewed funding, of which $1.9 million was from NCI and $15.1 was from other peer-review sponsors. From 2006-2010, members published 250 cancer-relevant, peer-reviewed papers which were cited 2904 times (average 10.8 citations/publication) of which 7% were the result of inter-programmatic interactions and 15% from intra-programmatic interactions. In addition, CB program members accounted for 10.2% of the usage of the Biospecimen Shared Resource, 7.09% of the usage of the Biostatistics & Informatics Shared Resource, and 8.57% of the usage of the Lead Development & Optimization Shared Resource in 2010. CB is jointly led by Yvonne Wan and Linheng Li, who bring complementary scientific expertise, growing leadership experience, and diverse institutional representation. They will work closely with Danny R. Welch, Associate Director for Basic Science. CB has taken advantage of historical strengths at KUMC, KU-Lawrence and the Stowers Institute in liver, Gl, kidney and hematopoietic tumors. Recent recruitments have expanded those initiatives to include breast, HNSCC, and osteosarcoma research. In addition to a disease-based thematic organization, CB members have expertise that can be organized into four discipline-based themes - Chromatin Organization and Transcriptional Regulation, Signaling Pathways and Development, Cancer Cell Biology and Stem Cell Biology; and Cell Proliferation, Differentiation and Death,